ArticleFrontiers in oncology2022
Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches.JTO clinical and research reports · 2026Review
- Thymic Neuroendocrine Tumor Presenting With Cervical Lymphadenopathy: A Case Report and Diagnostic Challenge.Clinical case reports · 2025Article
- Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review.Cancers · 2025Review
- SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.Journal of neuropathology and experimental neurology · 2025Article
- Translation of PET radiotracers for cancer imaging: recommendations from the National Cancer Imaging Translational Accelerator (NCITA) consensus meeting.BMC medicine · 2025Article
- SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma.Journal of clinical pathology · 2024Article
- Octreotide attenuates intestinal barrier damage by maintaining basal autophagy in Caco2 cells.Molecular medicine reports · 2024Article
- Top IHC/ISH Hacks for and Molecular Surrogates of Poorly Differentiated Sinonasal Small Round Cell Tumors.Head and neck pathology · 2024Review
- Theranostics with somatostatin receptor antagonists in SCLC: Correlation ofTheranostics · 2024Article
- Imaging of thymic epithelial tumors-a clinical practice review.Mediastinum (Hong Kong, China) · 2024Review
- CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Somatostatin receptor 2 (SSTR2) has been shown to be expressed in a subset of neuroendocrine tumors and carcinomas and plays a role in imaging studies and guiding therapy. Patients with tumors expressing SSTR2 may be successfully treated with somatostatin inhibitors or radiolabeled somatostatin analogues. We studied SSTR2 expression in TET and correlated it with 68Ga-DOTATATE PET/CT or 68Ga-DOTATATE PET/MR results and treatment outcome. An institutional database of TET was searched for thymoma, thymic carcinoma, and thymic neuroendocrine tumor (TNET) with available resection specimens. Cases were subtyped (2021 WHO classification) and staged (8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.